Press Releases
Press Releases
Twelve months ended 31 December 2023.
FY23 Revenue
Organic growth1
Price and volume/mix
Adjusted operating profit growth CER
Per share dividend proposed
FY24 organic revenue growth guidance2
Allocation for share buybacks in 2024
1 Organic revenue growth and adjusted operating profit are non-IFRS measures; definitions and calculations of non-IFRS measures can be found in our stock exchange announcement.
2 Definitions of organic revenue growth and adjusted operating profit can be found in our stock exchange announcement.
Performance driven by innovation, brand building and geographic and channel expansion.
Revenue by product category for the twelve months ended 31 December.
A clear approach to deliver on our growth ambitions is built on a world class portfolio of category leading brands in a growing sector across an attractive geographic footprint.
Launched Otrivin Nasal Mist in Poland, Portugal and Greece. This is a new exclusive technology to Haleon that delivers a more comfortable experience.
US launch of Tums + Sleep to help consumers with heartburn to fall asleep.
Voltaren launched Liquid Capsules in Italy and expanded its penetration of 24-hour patches globally.
In the US we launched ‘no-water needed’ Emergen-C crystals, which was named as the top innovation in the US immune support segment.
Sensodyne Pronamel Active Shield was named as one of the top two innovations in the US toothpaste market.
We enhanced our offering in allergy with Flonase Nighttime Allergy Relief, providing up to six hours’ relief from night time allergy symptoms.
We extended the range of Advil Dual Action to target back pain.
Sensodyne
Voltaren
Centrum
Parodontax
Advil
Otrivin
Polident
Sensodyne
Theraflu